In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. However, chemotherapy is not a treatment option for many men with pre-existing medical conditions or who cannot tolerate the side effects.

READ FULL ARTICLE Curated publisher From National Cancer Institute